Brendan O'Boyle
Contributor since: 2012
Articles
Is Valeant Giving Us A Warning About The S&P 500?
Interest Rates: Another Ominous Signal For The Market
How Has The S&P500 Performed In The Past When Earnings Declined By Over 10%?
Bonds Sell-Off: Is It Time For Risk-On In Stocks?
Biogen Sells Off On Short-Term Worries, But It's The Pipeline That Will Reward Long-Term Investors
At $49 Per Share, Realty Income Is Priced For Good, But Not Great Returns
If The Future Resembles The Past, Exxon Shareholders Have A Lot To Look Forward To
Recent Buy: Energy Transfer Partners
Travelers Misses On Revenue, But Is Still A Long-Term Buy
Your Biggest Risk In The Market May Not Be What You Think
Deere Has Been Stuck In Neutral, But The Seeds For Future Returns Have Been Sown
Pfizer Pays A Pretty Penny For Hospira: Here's What You Need To Know
Warren Buffett Is Right: The Fed Will Have A Tough Time Raising Rates In 2015
An Update On Epirus In Light Of Recent Developments
Consider This Before You Sell On Fears Of A Strong Dollar
Before You Short Tesla Remember This: Tesla Is Selling A Brand, Not A Car
The Hepatitis C Price War Begins: Gilead Plays To Win By Signing With CVS
The Oil Collapse: White Swan Or Black Swan?
Epirus Biopharma: A High Risk/High Reward Biosimilar Investment
Gilead Feels The Heat Of Competition
Be Careful With Gilead - It May Be Time To Take Profits
The Next Time You Evaluate A Stock Consider The Return At Constant Valuation
Legacy Reserves: The Time To Accumulate Is Now
What Bull Market? The Dow Jones Industrial Average Is Flat Since 2007...
Is A 30% Return In 2013 A Good Reason To Sell Your Stocks?
Buy Parexel International On Increasing Pharmaceutical Contract-Research Spending
Codexis Incorporated: A Strong Biopharma Turnaround Play
Deep Risk Or Shallow Risk: Should Investors Choose Stocks Or Bonds?
Year-End 2013: An Average Bull Market Year
Hospira Incorporated: Unappreciated Upside Due To A Promising Biosimilar Pipeline
Dude Where's My Taper?
Tetraphase Pharmaceuticals: A Compelling High-Risk / High-Reward Biotech Investment